The Relationship Between Prior Cancer Diagnosis and All-Cause Dementia Progression Among US Adults.
Aging
cancer
cognitive dysfunction
dementia
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
7
6
2022
medline:
27
7
2022
entrez:
6
6
2022
Statut:
ppublish
Résumé
Cancer-related cognitive impairment (CRCI), a frequent effect of cancer and its treatments, shares common cognitive symptoms with dementia syndromes. Cross-sectional studies demonstrate an inverse relationship between cancer and dementia. However, the longitudinal relationship between dementia decline and cancer has not been investigated. To evaluate the association between cancer and longitudinal progression of dementia. We extracted electronic health record data from July 2003 to February 2020 from a single academic medical center. We identified dementia and cancer history prior to dementia using ICD-9/10 codes. We measured cognitive decline with the Alabama Brief Cognitive Screener (ABCs). We used adjusted linear mixed models to estimate baseline cognition and rate of progression by cancer history, including differences by race. The study included 3,809 participants with dementia, of which 672 (17.6%) had cancer history. Those with cancer history had higher baseline cognition (β: 1.07, 95% CI: 0.45, 1.69), but similar rate of decline. Non-Hispanic Blacks had lower cognitive scores at baseline and throughout follow-up regardless of cancer status compared to non-Hispanic Whites and other races/ethnicities with and without cancer history. In this longitudinal retrospective study, participants with cancer history demonstrate better cognition at dementia diagnosis and no difference in cognitive decline than those without cancer history. Smoking and comorbidities attenuate this association and results indicate non-Hispanic Blacks have worse cognitive outcomes in dementia regardless of cancer history than other race/ethnicity groups. Further exploration of the role of smoking, comorbidities, and race/ethnicity on cancer and dementia-related cognitive decline is needed.
Sections du résumé
BACKGROUND
Cancer-related cognitive impairment (CRCI), a frequent effect of cancer and its treatments, shares common cognitive symptoms with dementia syndromes. Cross-sectional studies demonstrate an inverse relationship between cancer and dementia. However, the longitudinal relationship between dementia decline and cancer has not been investigated.
OBJECTIVE
To evaluate the association between cancer and longitudinal progression of dementia.
METHODS
We extracted electronic health record data from July 2003 to February 2020 from a single academic medical center. We identified dementia and cancer history prior to dementia using ICD-9/10 codes. We measured cognitive decline with the Alabama Brief Cognitive Screener (ABCs). We used adjusted linear mixed models to estimate baseline cognition and rate of progression by cancer history, including differences by race.
RESULTS
The study included 3,809 participants with dementia, of which 672 (17.6%) had cancer history. Those with cancer history had higher baseline cognition (β: 1.07, 95% CI: 0.45, 1.69), but similar rate of decline. Non-Hispanic Blacks had lower cognitive scores at baseline and throughout follow-up regardless of cancer status compared to non-Hispanic Whites and other races/ethnicities with and without cancer history.
CONCLUSION
In this longitudinal retrospective study, participants with cancer history demonstrate better cognition at dementia diagnosis and no difference in cognitive decline than those without cancer history. Smoking and comorbidities attenuate this association and results indicate non-Hispanic Blacks have worse cognitive outcomes in dementia regardless of cancer history than other race/ethnicity groups. Further exploration of the role of smoking, comorbidities, and race/ethnicity on cancer and dementia-related cognitive decline is needed.
Identifiants
pubmed: 35662118
pii: JAD220054
doi: 10.3233/JAD-220054
pmc: PMC9382674
mid: NIHMS1826624
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-535Subventions
Organisme : NIAMS NIH HHS
ID : K01 AR068400
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG057684
Pays : United States
Organisme : AHRQ HHS
ID : T32 HS013852
Pays : United States
Références
Med Care. 2002 Aug;40(8 Suppl):IV-26-35
pubmed: 12187165
Lancet Neurol. 2012 Nov;11(11):1006-12
pubmed: 23079557
Cancer Epidemiol Biomarkers Prev. 2018 May;27(5):541-549
pubmed: 29475966
Breast Cancer Res Treat. 2013 Jan;137(1):261-71
pubmed: 23143212
Circulation. 2007 May 1;115(17):2340-3
pubmed: 17470708
J Clin Oncol. 2018 Jan 1;36(1):25-33
pubmed: 29035642
Alzheimers Dement. 2017 Jan;13(1):28-37
pubmed: 27172148
CA Cancer J Clin. 2016 May;66(3):203-39
pubmed: 27002678
Dement Geriatr Cogn Disord. 2018;45(3-4):131-151
pubmed: 29734182
BMJ. 2012 Mar 12;344:e1442
pubmed: 22411920
PLoS One. 2017 Jun 20;12(6):e0179857
pubmed: 28632787
J Cereb Blood Flow Metab. 2018 Dec;38(12):2112-2128
pubmed: 30295560
Alzheimers Dement (N Y). 2020 Jun 14;6(1):e12039
pubmed: 32548238
J Neurol Neurosurg Psychiatry. 2002 Jul;73(1):40-4
pubmed: 12082043
BMC Geriatr. 2015 Mar 25;15:31
pubmed: 25879993
Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):306-14
pubmed: 19568149
Neuroepidemiology. 2018;50(3-4):207-215
pubmed: 29758558
J Oncol Pract. 2016 Jun;12(6):e633-42
pubmed: 27165489
Circ Cardiovasc Qual Outcomes. 2013 Sep 1;6(5):604-11
pubmed: 24021692
Neth J Med. 2016 Jun;74(5):201-9
pubmed: 27323673
J Pain Symptom Manage. 2017 Apr;53(4):682-692
pubmed: 28062341
JAMA Intern Med. 2015 Mar;175(3):401-7
pubmed: 25621434
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
CA Cancer J Clin. 2014 Jul-Aug;64(4):225-49
pubmed: 24916760
J Clin Oncol. 2016 Feb 20;34(6):611-35
pubmed: 26644543
Am J Clin Oncol. 2010 Dec;33(6):533-43
pubmed: 20023570
J Am Geriatr Soc. 1997 Aug;45(8):923-8
pubmed: 9256842
BMC Med Inform Decis Mak. 2013 Nov 20;13:128
pubmed: 24257030
Support Care Cancer. 2017 Mar;25(3):905-913
pubmed: 27837322
Acta Neuropathol. 2010 Sep;120(3):287-96
pubmed: 20623294
CA Cancer J Clin. 2015 Nov-Dec;65(6):428-55
pubmed: 26348643
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Prim Care Companion CNS Disord. 2019 Mar 14;21(2):
pubmed: 30896091
J Am Geriatr Soc. 2012 May;60(5):910-5
pubmed: 22587853
Med Clin North Am. 2017 Nov;101(6):1115-1134
pubmed: 28992858
Expert Rev Neurother. 2011 Nov;11(11):1579-91
pubmed: 22014137
Psychol Health Med. 2018 Dec;23(10):1182-1195
pubmed: 29901408
Med Clin North Am. 2017 Nov;101(6):1099-1113
pubmed: 28992857
Arch Neurol. 2011 Jan;68(1):58-66
pubmed: 21220675
Int J Med Inform. 2011 Jul;80(7):533-40
pubmed: 21514880
Ann Surg Oncol. 2021 Dec;28(13):8162-8171
pubmed: 34036428
Am J Geriatr Psychiatry. 2017 Dec;25(12):1415-1426
pubmed: 28495470
Curr Psychiatry Rep. 2016 Sep;18(9):85
pubmed: 27481112
J Health Soc Behav. 2001 Sep;42(3):258-76
pubmed: 11668773
Alzheimers Dement. 2021 Jan;17(1):70-80
pubmed: 32827354
J Alzheimers Dis. 2020;76(2):691-701
pubmed: 32538844
J Natl Cancer Inst. 2013 Jun 5;105(11):823-32
pubmed: 23539755
Cancer. 2010 Jul 15;116(14):3348-56
pubmed: 20564075
Br J Cancer. 2021 Jan;124(2):315-332
pubmed: 32901135
Neurol Sci. 2015 Nov;36(11):1987-94
pubmed: 26248482
JAMA Neurol. 2020 Apr 1;77(4):451-460
pubmed: 31904767
Cancer Causes Control. 2013 May;24(5):847-60
pubmed: 23549959
Alzheimers Dement. 2019 Feb;15(2):292-312
pubmed: 30555031
J Geriatr Oncol. 2019 Sep;10(5):779-786
pubmed: 30389494
Acta Cytol. 2016;60(6):518-526
pubmed: 27825171
Neurology. 2015 Aug 11;85(6):528-34
pubmed: 26180136
Syst Rev. 2017 Dec 19;6(1):259
pubmed: 29258596